Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REM0046127 oral suspension versus placebo in mild to moderate Alzheimer's disease
NL-OMON53612Phase 2Completed
- Sponsor
- reMYND
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing REM0046127 oral suspension with Placebo suspension (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events. Started Sep 2022; status: completed.
02
Drugs
rem0046127
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON53612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53612.